NCT02061423View on ClinicalTrials.gov

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 8, 2014

Primary Completion Date

February 28, 2019

Study Completion Date

February 21, 2024

Conditions
Breast Cancer
Interventions
BIOLOGICAL

HER-2 pulsed Dendritic Cell Vaccine

Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.

Trial Locations (2)

19104

Hospital of the University of Pennsylvania, Philadelphia

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT02061423 - HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy | Biotech Hunter | Biotech Hunter